Table 1 Patients’ characteristics at the start of EVG/COB/TFV/FTC + DRV (n = 39)
Age, median (IQR), years | 42 (34–50) |
|---|---|
Female | 5 (12.8) |
Mode of transmission | |
Men who have sex with men | 19 (48.7) |
Heterosexual | 13 (33.3) |
Injecting drug user | 5 (12.8) |
Other/unknown | 2 (5.1) |
Geographic origin | |
Spanish | 14 (33.3) |
Foreign-born | 24 (61.5) |
Unknown | 1 (2.4) |
Viral load, median (IQR), copies/ml | 379 (40–12,000) |
CD4 count, median (IQR), cells/microl | 437 (108–740) |
Viral load | |
< 50 copies/ml | 10 (25.6) |
≥ 50 copies/ml | 29 (74.4) |
Years since starting ART, median (IQR) | 5.3 (2.5–7.5) |
Number of prior regimens, median (IQR) | 3 (2–6) |
Previous ART regimen | |
ART daily pill burden, median (IQR) | 2 (1–5) |
At least 3 pills per day | 17 (43.6) |
At least twice daily ART dosing | 11 (28.2) |
Reasons for switching to EVG/COB/TFV/FTC + DRV | |
Virologic failure | 14 (35.9) |
Simplification | 10 (25.6) |
Toxicity | 4 (10.3) |
Non-adherence | 2 (5.1) |
Unknown | 9 (23.1) |